Interrogating Epigenetic Changes in Cancer Genomes
探究癌症基因组的表观遗传变化
基本信息
- 批准号:8628066
- 负责人:
- 金额:$ 163.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsAndrogen ReceptorAndrogensAreaAwardBayesian ModelingBindingBinding SitesBiochemical GeneticsBiological AssayBiological MarkersCancer PatientCancer cell lineCellsChromatin LoopChromatin StructureChromatin Structure AlterationChromosomesComputer SimulationDNA FingerprintingDNA MethylationDNA Polymerase IIDataDistantEnvironmentEpigenetic ProcessEstrogen ReceptorsEstrogensFingerprintGene SilencingGene TargetingGenetic TranscriptionGenomicsHistonesHormonesIn VitroInstructionKnock-in MouseLawsLeadLigandsMADH4 geneMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of prostateMediatingMethylationModelingNeoplastic Cell TransformationNormal CellPatternPattern RecognitionPhenotypePlayPrimary NeoplasmPromoter RegionsPropertyProtein KinaseRNAResearch PersonnelResistanceRoleScanningScientistSignal TransductionStatistical MethodsSystemTechniquesTestingTimeTrainingTranscriptional RegulationValidationbasecancer cellcancer genomechemotherapychromatin remodelingepigenetic markerepigenomicsgenome-widehistone modificationmalignant breast neoplasmmarkov modelpromoterprostate cancer cellresearch studyresponsespatiotemporaltranscription factortranslational study
项目摘要
At our proposed U54 center, we will continue to conduct epigenomic analysis in cancer. While the focus of
the previous award was on epigenetic processes associated with neoplastic transformation of normal cells.
In this competing application, we will move a step forward to study epigenetic changes in prostate, breast,
and ovarian cancer cells progressing to an aggressive phenotype, i.e., hormone-Zchemo-resistance. Based
on our preliminary findings, we hypothesize that epigenetic deregulation of androgen receptor, estrogen
receptor a, or TGF-p/SMAD4 signaling underlies the transition of a hormone-Zchemo-sensitive to a hormone-
Zchemo-insensitive phenotype in cancer. Different modes of signaling-mediated transcription, including
ligand-dependent and -independent functions, will be defined using integrated epigenomic data. We will
develop probabilistic algorithms to predict the effect of chromosome looping and chromatin remodeling (i.e.,
changes of histone marks and DNA methylation) on target gene transcription, including empirical Bayesian
mixture and hidden Markov modeling (for classifying spatiotemporal patterns of target genes in a signaling
network), interactive modeling of transcription "hubs", stochastic modeling of permissive and non-permissive
epigenetic marks, and pattern recognition algorithms for predicting transcription factor binding sites and
methylation-prone or -resistant sequences. Testing and validation of these computational predictions will be
performed in cancer cell lines. Assays including functional knock-in or -out of key transcription hubs will
determine whether cancer cells gain or lose hormone-Zchemo-sensitivity, respectively, as a result of in vitro
manipulation. For translational studies, primary tumors will be used to correlate clinicopathological
correlations with epigenetic changes. By taking an integrative "omics" approach, we expect to move the
epigenomics field forward in at least three new directions: 1) long-range chromatin looping may be a
common epigenetic mechanism of transcriptional regulation in cancer; 2) histone modificationsZDNA
methylation of distant transcription binding sites represent previously uncharacterized biomarkers for
predicting hormone-Zchemo-resistance in cancer subtypes; and 3) computational modeling may support the
recent notion that repressive histone modifications, rather than DNA methylation, are critical epigenetic
factors in the heritable silencing of genes. Importantly, these state-of-the-art computational approaches and
the vast omics data will be used for our educationZoutreach efforts to train young systems scientists and for
collaborative studies with other researchers in the CCSB-ICBP network.
在我们提议的U 54中心,我们将继续进行癌症的表观基因组分析。虽然重点是
上一个奖项是关于与正常细胞的肿瘤转化有关的表观遗传过程。
在这个竞争性的应用中,我们将向前迈进一步,研究前列腺、乳腺、
和卵巢癌细胞进展为侵袭性表型,即,抗化疗药物基于
根据我们的初步发现,我们假设雄激素受体、雌激素
受体a或TGF-β/SMAD 4信号转导是细胞对激素敏感的转变的基础,
癌症中的Zchemo不敏感表型。不同模式的信号传导介导的转录,包括
配体依赖性和非依赖性功能,将使用整合的表观基因组数据来定义。我们将
开发概率算法来预测染色体成环和染色质重塑的影响(即,
组蛋白标记和DNA甲基化)对靶基因转录的影响,包括经验贝叶斯
混合和隐马尔可夫建模(用于对信号转导中的靶基因的时空模式进行分类)
网络),转录“枢纽”的交互式建模,许可和非许可的随机建模
表观遗传标记和用于预测转录因子结合位点的模式识别算法,
易甲基化或耐甲基化序列。这些计算预测的测试和验证将是
在癌细胞系中进行。包括关键转录枢纽的功能性敲入或敲出的测定将
确定癌细胞是否获得或失去化疗敏感性,分别作为体外结果,
操纵对于转化研究,原发性肿瘤将用于与临床病理学相关性。
与表观遗传变化的相关性。通过采取综合的“组学”方法,我们希望将
表观基因组学领域至少有三个新的方向:1)长距离染色质环可能是一个
癌症转录调控的常见表观遗传机制; 2)组蛋白修饰ZDNA
远端转录结合位点的甲基化代表了以前未表征的生物标志物,
预测癌症亚型的耐药;和3)计算建模可以支持
最近的观点认为,抑制性组蛋白修饰,而不是DNA甲基化,是关键的表观遗传
基因沉默的遗传因素。重要的是,这些最先进的计算方法和
大量的组学数据将用于我们的教育,培训年轻的系统科学家,
与CCSB-ICBP网络中的其他研究人员进行合作研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tim H.-M. Huang其他文献
ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer
- DOI:
10.1186/s12920-020-0729-7 - 发表时间:
2020-05-14 - 期刊:
- 影响因子:2.000
- 作者:
Chun-Lin Lin;Xi Tan;Meizhen Chen;Meena Kusi;Chia-Nung Hung;Chih-Wei Chou;Ya-Ting Hsu;Chiou-Miin Wang;Nameer Kirma;Chun-Liang Chen;Ching-Hung Lin;Kate I. Lathrop;Richard Elledge;Virginia G. Kaklamani;Kohzoh Mitsuya;Tim H.-M. Huang - 通讯作者:
Tim H.-M. Huang
Tim H.-M. Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tim H.-M. Huang', 18)}}的其他基金
PAI-1-mediated early-onset endometrial cancer
PAI-1介导的早发性子宫内膜癌
- 批准号:
10609901 - 财政年份:2021
- 资助金额:
$ 163.14万 - 项目类别:
PAI-1-mediated early-onset endometrial cancer
PAI-1介导的早发性子宫内膜癌
- 批准号:
10410371 - 财政年份:2021
- 资助金额:
$ 163.14万 - 项目类别:
Novel epigenetic paradigm in endometrial cancer recurrence
子宫内膜癌复发的新表观遗传学范例
- 批准号:
8755016 - 财政年份:2014
- 资助金额:
$ 163.14万 - 项目类别:
Novel epigenetic paradigm in endometrial cancer recurrence
子宫内膜癌复发的新表观遗传学范例
- 批准号:
9124596 - 财政年份:2014
- 资助金额:
$ 163.14万 - 项目类别:
Interrogating Epigenetic Changes in Cancer Genomes
探究癌症基因组的表观遗传变化
- 批准号:
8340013 - 财政年份:2011
- 资助金额:
$ 163.14万 - 项目类别:
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer
组合环境化学物质改变乳腺癌的易感性
- 批准号:
8280369 - 财政年份:2010
- 资助金额:
$ 163.14万 - 项目类别:
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer
组合环境化学物质改变乳腺癌的易感性
- 批准号:
8011571 - 财政年份:2010
- 资助金额:
$ 163.14万 - 项目类别:
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer
组合环境化学物质改变乳腺癌的易感性
- 批准号:
8472494 - 财政年份:2010
- 资助金额:
$ 163.14万 - 项目类别:
Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer
组合环境化学物质改变乳腺癌的易感性
- 批准号:
8150389 - 财政年份:2010
- 资助金额:
$ 163.14万 - 项目类别:
Epigenomics of Bisphenol A Exposure and Disease Risk
双酚 A 暴露和疾病风险的表观基因组学
- 批准号:
7714035 - 财政年份:2009
- 资助金额:
$ 163.14万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 163.14万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 163.14万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 163.14万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 163.14万 - 项目类别: